Related Experiment Videos
Radioimmunoguided surgery using monoclonal antibody.
E W Martin1, C M Mojzisik, G H Hinkle
1Department of Surgery, Ohio State University College of Medicine, Columbus.
American Journal of Surgery
|November 1, 1988
Summary
Radioimmunoguided surgery using monoclonal antibody B72.3 showed potential for intraoperative tumor detection. This technique identified tumors in 71.2% of patients, highlighting its promise in surgical oncology.
Area of Science:
- Oncology
- Surgical Oncology
- Immunodiagnostics
Background:
- Intraoperative tumor detection remains a challenge in surgical oncology.
- Accurate identification of malignant tissues is crucial for complete tumor resection and improved patient outcomes.
Purpose of the Study:
- To assess the efficacy of radioimmunoguided surgery (RIGS) using a labeled monoclonal antibody B72.3 for intraoperative tumor detection.
- To evaluate the performance of RIGS across various cancer types, including colon, gastric, breast, and ovarian cancers.
Main Methods:
- 66 patients with confirmed tumors received preoperative injections of monoclonal antibody B72.3.
- A hand-held gamma-detecting probe was utilized during surgery to identify tumor presence.
- Tumor detection was based on probe counts and tumor-to-adjacent normal tissue ratios.
Main Results:
- RIGS detected tumors in 83% of primary colon cancer and 79% of recurrent colon cancer cases.
- Detection rates varied for other cancers: 80% for gastric, 37.5% for breast, and 50% for ovarian cancer.
- Overall, RIGS identified tumors in 71.2% of patients, with 9.1% borderline positive and 19.7% system failures.
Conclusions:
- Radioimmunoguided surgery with B72.3 demonstrates significant potential for intraoperative tumor localization.
- Further advancements in antibody engineering and patient selection may enhance RIGS performance.
- RIGS offers a promising tool to improve surgical precision in oncology.